Post-earnings recap
Reported
Thu, Feb 5, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
AstraZeneca's earnings report showed a miss on EPS, which likely contributed to the stock's decline of 2.55%. Investors may be concerned about the company's performance, especially since no additional guidance or commentary was provided. The lack of revenue data also leaves uncertainty about overall business health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.76 | N/A | -9.52% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.